Delighted to present our full-length scRNA-seq study on ovarian cancer patients, in collaboration with the University Hospital Basel @labfranz ! https://t.co/I7LnLDd2gr
Can we simultaneously detect isoform-level gene expression, mutations and gene fusions in cancer cells? 1/
Pleased to share our review discussing the future of #prostatecancer patient-derived #xenografts published in @NatRevUrol . Great effort tackling this topic from Mitchell Lawrence, @ReneaTaylor1, and Gail Risbridger:
https://t.co/lP4Cg1xdeh
Detection of isoforms and genomic alterations by high-throughput full-length single-cell RNA sequencing for personalized oncology https://t.co/g7ZPnXN34v #bioRxiv
Join our team!!
Xmas came early in the form of a grant 😁
We are looking to fill TWO postdoc positions in chemoenzymatic and/or carbohydrate synthesis, with a focus on developing new glycan-based antimicrobial therapies.
#GlycoTime#ChemPostdoc
More info in thread 👇👇👇
Cancer cells use sugar molecules on their surface to disable attacks by the body’s immune system. Researchers at the University of Basel now report on how this mechanism can be neutralized.
@LImmunotherapy@DepBiomedicine@UniSpitalBasel
https://t.co/f6GK3imn1Y
Making glycosylation "hot" for cancer immunotherapy: wonderful collaboration with Heinz Läubli @LImmunotherapy at @DepBiomedicine and @UniSpitalBasel
https://t.co/HHvHambT5H
Much appreciated, thanks !
Recent review together with Daniel Maslyar and Sam Nalle on Siglecs and sialic acids as target for cancer immunotherapy #glycotime#Immunotherapy
Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches https://t.co/NVnFchMryp
Registration now open for Glycobasque 5
18-19 November 2022, San Sebastian, Spain
keynotes:
Henrik Clausen, DK
Geert-Jan Boons, NL, USA
M.G. Finn, USA
Sabine Flitsch, UK
details: https://t.co/FHW79Cf0vT